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Background:  The chemotherapy use process is considered as potentially risky for cancer patients due to its complex 
process, use of agents with narrow therapeutic indeces, multiple drug use and use of potentially toxic compounds adding 
to morbidity and mortality for patients with cancer9LQFULVWLQHD³+LJK$OHUW´PHGLFLQHKDVEHHQDVVRFLDWHGZLWKIDWDOEXW
preventable medication errors. 
Objective:   To determine hazards associated with vincristine use process by performing proactive risk assessments 
using Healthcare Failure Mode Effect Analysis (HFMEA).  
Methods:   A multidisciplinary health team identified and evaluated potential failure modes based on vincristine use 
process flow diagram using a hazard scoring matrix in a leading referral hospital in Kenya treating patients with cancer.  
The hazard score matrix was based on the published literature. Failure modes were prioritized using decision tree 
analysis in which recommendations to counteract the risks were determined.  
Results:   The processes evaluated were; prescribing, preparation and dispensing, transportation and storage, 
administration and monitoring of use. A total of 77 failure modes were identified over the 3 months period of the study, 
April to June 2017, of which 25 were classified as high risk. Thirteen were adequately covered by existing control 
measures while the other 12 required the development of mitigation strategies.  Two of the 12 failure modes were single-
point weaknesses.  
Conclusions:    
Multiple medication errors, some with serious consequences, can occur at each stage of the chemotherapy use process 
making it a high-risk process. HFMEA is a useful tool to identify improvements to medication safety and reduce patient 
harm. The HFMEA process brings together the multidisciplinary team involved in patient care in actively identifying 
potential failure modes and therefore owning the recommendations made. This is now being followed up.  
 
